Recently, Rossi et al. demonstrated that the levels of interleukin-6 (IL-6), hepatocyte growth factor (HGF), and monocyte chemotactic protein 2 (MCP-2), found in the serum of patients with melanoma whose disease did not respond to ICI, are higher compared to ICI-responders [155]. The gene discussed is HGF; the disease is melanoma.